Switch theme
Sign up to access all valuation multiples
Guilin Sanjin Pharmaceutical Co Ltd is engaged in research and development of proprietary Chinese medicines and natural medicines.
2001
752
LTM Revenue n/a
LTM EBITDA n/a
$977M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guilin Sanjin has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Guilin Sanjin achieved revenue of $299M and an EBITDA of $89.5M.
Guilin Sanjin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guilin Sanjin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $299M | n/a | XXX | XXX | XXX |
| Gross Profit | $178M | $192M | XXX | XXX | XXX |
| Gross Margin | 60% | NaN% | XXX | XXX | XXX |
| EBITDA | $89.5M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 30% | NaN% | XXX | XXX | XXX |
| Net Profit | $47.4M | $45.4M | XXX | XXX | XXX |
| Net Margin | 16% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 18, 2025, Guilin Sanjin's stock price is CNY 14 (or $2).
Guilin Sanjin has current market cap of CNY 8.0B (or $1.1B), and EV of CNY 7.1B (or $977M).
See Guilin Sanjin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $977M | $1.1B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 18, 2025, Guilin Sanjin has market cap of $1.1B and EV of $977M.
Guilin Sanjin's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Guilin Sanjin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Guilin Sanjin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $977M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGuilin Sanjin's NTM/LTM revenue growth is n/a
Guilin Sanjin's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Guilin Sanjin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Guilin Sanjin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Guilin Sanjin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guilin Sanjin acquired XXX companies to date.
Last acquisition by Guilin Sanjin was XXXXXXXX, XXXXX XXXXX XXXXXX . Guilin Sanjin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Guilin Sanjin founded? | Guilin Sanjin was founded in 2001. |
| Where is Guilin Sanjin headquartered? | Guilin Sanjin is headquartered in China. |
| How many employees does Guilin Sanjin have? | As of today, Guilin Sanjin has 752 employees. |
| Is Guilin Sanjin publicy listed? | Yes, Guilin Sanjin is a public company listed on SHE. |
| What is the stock symbol of Guilin Sanjin? | Guilin Sanjin trades under 002275 ticker. |
| When did Guilin Sanjin go public? | Guilin Sanjin went public in 2009. |
| Who are competitors of Guilin Sanjin? | Similar companies to Guilin Sanjin include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Guilin Sanjin? | Guilin Sanjin's current market cap is $1.1B |
| Is Guilin Sanjin profitable? | Yes, Guilin Sanjin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
